MedTrace Logo

An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay

NCT01507155 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 685

Last updated 2016-06-08

Study results available
· View outcomes & findings →

Summary

Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1. Subjects (patients who have consented to using the Genecept Assay) and 2. Clinician study participants (clinicians who have ordered the Assay on behalf of their patients). This study will involve the collection of responses from both Subjects and clinician study participants with the intention of correlating this information to Subject genetic data.

Conditions

Interventions

DEVICE

Genecept Assay

Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders

Sponsors & Collaborators

  • Genomind, LLC

    lead INDUSTRY

Principal Investigators

  • Herb Harris, MD, PhD · Genomind, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01507155 on ClinicalTrials.gov